HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.00330705v1 1/1/148    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grantham, J. J. Articles by Torres, V. E. Search for Related Content PubMed PubMed Citation Articles by Grantham, J. J. Articles by Torres, V. E. Related Collections Related Article

Volume Progression in Autosomal Dominant Polycystic Kidney Disease: The Major Factor Determining Clinical Outcomes

Jared J. Grantham^*, Arlene B. Chapman, and Vicente E. Torres

^* Kansas University Medical Center, Kansas City, Kansas; Emory University, Atlanta, Georgia; and Mayo Clinic College of Medicine, Rochester, Minnesota

Address correspondence to: Dr. Jared J. Grantham, The Kidney Institute, Mailstop 3018, University of Kansas, Kansas City, Kansas 66103. Phone: 913-588-7605; Fax: 913-588-7606; jgrantha{at}kumc.edu

Autosomal dominant polycystic kidney disease (PKD) is a hereditary condition characterized by the progressive enlargement of innumerable renal cysts that contribute to life-altering morbidity early in the course of the disease. Evidence indicates that the rate of increase in kidney volume can be reliably measured by magnetic resonance or computed tomography imaging, thus providing objective means to judge the effectiveness of therapies that are targeted to the aberrant growth of renal tubules. It is now possible, therefore, to monitor the effectiveness of potential therapies on the signature abnormality in autosomal dominant PKD before irreversible damage has been done by the cysts. Evidence accumulated from human cross-sectional and longitudinal studies and longitudinal studies of PKD models in animals provide strong support for the view that reducing the rate of kidney volume enlargement will ameliorate the late-stage development of renal insufficiency.

Related Article

Calcium Restores a Normal Proliferation Phenotype in Human Polycystic Kidney Disease Epithelial Cells

Tamio Yamaguchi, Scott J. Hempson, Gail A. Reif, Anne-Marie Hedge, and Darren P. Wallace
J. Am. Soc. Nephrol. 2006 17: 178-187. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				J. J. Grantham Autosomal Dominant Polycystic Kidney Disease N. Engl. J. Med., October 2, 2008; 359(14): 1477 - 1485. [Full Text] [PDF]

				J. P. Calvet Strategies to Inhibit Cyst Formation in ADPKD Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1205 - 1211. [Abstract] [Full Text] [PDF]

				T. I. Steinman Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant., February 1, 2008; 23(2): 431 - 433. [Full Text] [PDF]